# A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults

> **NCT03824236** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 61 (actual)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** RTS,S/AS01E (SB257049)

## Key facts

- **NCT ID:** NCT03824236
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-05
- **Primary completion:** 2019-04-30
- **Final completion:** 2019-09-26
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2020-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03824236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03824236, "A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03824236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*